Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the effects of intravitreal ranibizumab (IVR) as adjunctive treatment for
trabeculectomy with mitomycin C (TMC) in neovascular glaucoma (NVG).